Indonesia’s state-owned hospitals prepare isolation rooms as COVID-19 cases up

JAKARTA, Mar 16, 2020 – (ACN Newswire) – State-owned hospitals, under the Indonesian Healthcare Corporation (IHC) Pertamedika, will help the government handle the spread of coronavirus (COVID-19), including through treating and isolating patients at their facilities, State-Owned Enterprises Minister Erick Thohir stated.

"There are in all 65 state-owned hospitals, with special treatment rooms and 155 beds, and 66 safe houses," he noted in a statement received in Jakarta, Monday. He made the statement during a visit to the Pertamina Jaya Hospital in Jakarta on Thursday (Mar 12).

The number of people infected with COVID-19 in Indonesia continues to grow, with government spokesperson for COVID-19 handling, Achmad Yurianto, declaring that 117 had confirmed positive for the virus in Indonesia as of 5 a.m. local time on Monday (Mar 16).

Minister Thohir expressed confidence in the hospitals, under the state-owned facilities' network, and their abilities to offer treatments to those diagnosed with COVID-19.

"I am very confident. They can also provide better treatment than those offered at private hospitals, as we focus on serving the people rather than on mere business profits," he stated.

IHC Pertamedika comprises 65 hospitals located across Indonesia. Four facilities in Jakarta and Banten, include the Central Pertamina hospital, Krakatau Medika hospital, Pertamina Jaya hospital, and Pelni hospital.

Meanwhile, Central Java and East Java are home to the PHC hospital in Surabaya, Lavalette hospital in Semarang, Cirebon hospital, and Cilacap hospital.

The 12 hospitals located in Sumatra include the Plaju hospital in South Sumatra, Bakti Tuman Muntok hospital in Bangka Belitung, Prima Inti Medika hospital in Aceh, and Pangkalan Brandan hospital in North Sumatra.

Meanwhile, Kalimantan houses five health facilities: the Balikpapan hospital, Tanjung hospital and Danau Salak hospital in South Kalimantan, Parindu hospital in West Kalimantan, and Tarakan hospital in North Kalimantan.

In the eastern part of the country, an IHC Pertamedika hospital is located in Sorong, West Papua, with the Sorong hospital.

Director of IHC Pertamedika Dr. Fathema Djan Rachmat had informed ANTARA recently that apart from isolation rooms with negative pressure, she had prepared standard operational procedures for the treatment of patients under observation for COVID-19.

Rachmat also spoke of IHC Pertamedika having developed a tracking system to find potential cases.

"Indonesia stands united against this pandemic, so we need to develop a tracking system to identify patients or people under surveillance," she explained. — Antara.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Coronavirus Drug Development Update from NanoViricides, Inc.

SHELTON, CT / ACCESSWIRE, Mar 16, 2020 – (ACN Newswire) – NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19.

The Company has completed the synthesis of a number of nanoviricide drug candidates for testing in just a few weeks after identification of virus-binding ligands. This was possible because the Company is boot-strapping its efforts on the basis of its inventory of novel custom chemicals in hand. Additionally, the polymer backbone was previously manufactured in multi-kilogram quantities. However, there can be no assurance that any of these candidates would show sufficient effectiveness and safety for human clinical development at this time.

The Company has acquired and expanded two different, low-threat circulating coronaviruses in its own BSL2 lab, and has already expanded them to enable testing of drug candidates. One of these coronaviruses, namely NL63, uses the same ACE2 receptor on human cells as SARS-CoV-2, although it does not cause a similar severe disease in humans.

If the Company's test candidates are effective against these cell culture studies against coronaviruses, then that would provide a strong rationale that they may be expected to be effective against the current SARS-CoV-2. Presently, the Company does not have any collaboration established for further testing of its drug candidates against SARS-CoV-2. The Company is working to establish such collaborations, however, there can be no assurance that we will be successful in establishing the necessary collaborations or that our drug candidates will succeed in further testing. In the past, the Company has established and worked on collaborations with the U.S. Center for Diseases Control and Prevention (CDC), as well as the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

The Company has already successfully developed antiviral drug testing assays based on cell culture infection of certain low-threat coronaviruses viruses in our own BSL2 certified virology lab. Development of an assay to test the effectiveness of a drug candidate is an important milestone in the drug development process. We have been able to complete this milestone in just a few weeks because of the extensive experience and expertise in medium throughput drug testing antiviral assays development of our Senior Virologist.

Testing of our drug candidates against these BSL2 coronavirus strains is expected to begin shortly in our BSL2 virology lab.

As of March 11th, SARS-CoV-2 has caused at least 800 confirmed cases in more than 30 states, and the virus has led to more than 26 deaths in the U.S., with area lockdowns, quarantines, and state of emergency being declared in several states. The entire country of Italy is under quarantine. Japan is also experiencing a severe outbreak. This COVID-19 outbreak has caused cases in at least 99 countries, with confirmed cases totaling over 110,000, of which 62,000 have already recovered, with deaths of over 3,800 patients, according to CBS news (https://www.cbsnews.com/live-updates/coronavirus-outbreak-death-toll-us-infections-latest-news-updates-2020-03-09/). The health risks associated with the virus rise significantly with age and many younger, otherwise healthy people who contract it might show only mild symptoms, if any. It appears that the outbreaks in China and in South Korea are now showing signs of being controlled, with new cases having decreased significantly.

The U.S. Government has approved $8.3 Billion for COVID-19 response that includes development of drugs as well as vaccines, patient care, containment, and education, in a holistic approach.

Although vaccine development has started very quickly against the SARS-CoV-2, an effective vaccine may take at least 12-18 months before it can be used to treat patients.

Viruses are known to escape antibody drugs and vaccines via mutations, although, in contrast, the NanoViricides platform technology enables development of a drug that a virus is unlikely to escape by mutation. This is because we develop biomimetics that are designed to interfere with the virus binding to its cognate cellular receptor, and are further capable of disabling the virus from binding to cells. Coronaviruses mutate less rapidly than other RNA viruses such as influenza and HIV.

One of the coronaviruses we are using for testing of our drug candidates uses the same ACE2 receptor as the current SARS-CoV-2 virus (aka nCoV-2019). However, this coronavirus does not cause similar, severe disease in humans. Another coronavirus we are testing against uses a different but somewhat related receptor (in terms of biophysics). Investigating against both of these strains would allow us to examine which of the test candidates have more broad-spectrum effectiveness. However, there can be no assurance that successful results against these forms of coronavirus will lead to similar results against nCoV-2019 aka SARS-CoV-2. Moreover, the path to typical or standard drug development of any pharmaceutical product is extremely lenghty and requires substantial capital. However, regulatory agencies in China created expedited processes to enable rapid clinical testing of exploratory drug candidates. Accelerated pathways were also developed for enabling anti-Ebola clinical drug candidates in the 2017-18 epidemic in DRC. Nevertheless, there can be no assurance that even successful results against SARS-CoV-2 will lead to successful clinical trials or a successful pharmaceutical product, which is true of every drug development effort against SARS-CoV-2 at present.

Previously, on January 30th, the Company confirmed that it is working on a drug to treat the SARS-Cov-2 virus infections. The Company said that it had successfully completed the important milestone of finding potential virus-binding ligands that mimic the ACE2 interaction with SARS-CoV (2002) using molecular modeling. The current coronavirus strain, namely SARS-CoV-2 is closely related to the 2002 SARS-CoV, and uses the same human cellular receptor. We have now completed the next two milestones, namely synthesis of test candidates, and development of anti-CoV assays for testing them.

About NanoViricides

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company does not currently have a license to the coronavirus field, however, TheraCour has not denied any licenses to the Company. The Company typically begins the licensing process only after demonstrating effectiveness of some candidates in optimization stage.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Hua Medicine Announces 2019 Annual Results

SHANGHAI, Mar 16, 2020 – (ACN Newswire) – Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. For the year ended December 31, 2019, the Company incurred approximately RMB468.5 million in total expenses, of which approximately RMB 321.9 million was research and development expenses. As of December 31, 2019, the Company's cash position was approximately RMB 1,105.6 million.

Hua Medicine will continue to execute on its strategic goal of becoming a global diabetes care and management company, and is devoted to the development, registration and launch of dorzagliatin (HMS5552) in China and around the world. Hua Medicine achieved many milestones in 2019. The core scientific concept for dorzagliatin as a first-in-class drug was further validated, and the dorzagliatin-driven portfolio of diabetes therapies reflected in our pipeline continued to expand and advance. The Phase III monotherapy trial (HMM0301) for dorzagliatin (HMS5552) achieved its primary efficacy endpoint. The study results indicated that dorzagliatin was well tolerated during the 24-week study period, exhibited very low incidences of hypoglycemia and had a good safety profile. Meanwhile, two Phase I clinical trials with dorzagliatin (HMM0110 and HMM0111) also demonstrated satisfactory results. The results of HMM0110 demonstrated that dorzagliatin has the potential to be used in Type 2 diabetes (T2D) patients with moderate, severe and end stage chronic kidney disease (i.e., stages 3-5 of CKD); several top-selling oral anti-diabetes drugs must undergo dose adjustment (e.g., metformin and sitagliptin) when used for such T2D patients, or simply can't be used at all for such patients (e.g., select SGLT-2 inhibitors). The results of HMM0111 confirmed the clinical advantages and potential synergies of dorzagliatin in combination with sitagliptin (a DPP-4 inhibitor), one of the best-selling oral anti-diabetic drugs globally.

The diagnosis rate of Type 2 diabetes is relatively low in China. Accordingly, there is a huge population of non-diagnosed and drug-naive T2D patients in China, which provides a big market opportunity for dorzagliatin. Current diabetes therapies still cannot effectively restore the healthy body's ability to control blood glucose level autonomously, nor modify or stop the progression of diabetes into more advanced stages of the disease, leading to the development of diabetes-associated complications. In contrast, the results of pre-clinical and clinical studies (both completed and those currently under development) demonstrate that dorzagliatin has the potential to treat the underlying cause of Type 2 diabetes by fixing the impaired glucose sensor in all T2D patients and thereby restoring glucose homeostasis. Research data to date suggests that, as a cornerstone therapy, dorzagliatin possesses the potential of controlling the development of diabetes and preventing or delaying the occurrence of complications, either via monotherapy or through combination with currently available diabetes therapies.

"We will carry on implementing our developmental strategy, which consists of expanding in three dimensions: new products, global markets and new disease indications. By deploying dorzagliatin as a cornerstone therapy, we will establish an innovative, sharing and win-win scientific platform that focuses on the remodeling of glucose homeostasis, and eventually realize the personalized medicine of diabetes globally," said Dr. Li Chen, Founder and Chief Executive Officer of Hua Medicine.

Clinical trial Highlights

– Achieved 24-week primary efficacy endpoint in a double blinded placebo controlled Phase III trial in drug naive Type 2 diabetes (T2D) patients in China (HMM0301), with very low hypoglycemia incidents and good safety profiles. As of March 2, 2020, the last patient out, 52-week (plus one-week follow-up) patient visit for HMM0301 was completed.
– Completed enrollment in a metformin add-on Phase III registration trial (HMM0302). As of February 16, 2020, the 24-week patient visit for HMM0302 was completed.
– Completed HMM0110, which demonstrated desirable pharmacokinetics profile in patients with end stage chronic kidney disease, indicating the potential use of dorzagliatin among T2D patients with moderate, severe and end stage chronic kidney disease (i.e. stages 3-5 of CKD).
– Completed HMM0111, which investigated the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of dorzagliatin either alone or in combination with sitagliptin (a DPP-4 inhibitor) in T2D patients, and demonstrated combination and synergy potential between the two drugs.
– Granted a formulation patent for dorzagliatin in China.
– Filed six patent applications covering the IPR of fixed dose combination of dorzagliatin with six classes of oral anti-diabetic drugs.
– Fully validated the cGMP (current Good Manufacturing Practice) commercial manufacturing processes for active pharmaceutical ingredient (API) and drug product to support the launch of dorzagliatin in China.

Operational highlights

– Initiated a formal collaboration relating to the central role of glucokinase in controlling glucose homeostasis with Dr. Franz Matschinsky,professor of Biochemistry and Biophysics, Institute for Diabetes, Obesity and Metabolism Perelman School of Medicine, Philadelphia and the recipient of the 1995 Banting Medal for Scientific Achievement and the 2020 Rolf Luft Award.
– Presented AI-based machine learning results at the American Diabetes Association's 79th Scientific Sessions, providing a non-biased methodology to sub-classify T2D patients.
– Announced that global operation headquarters and research and development center were established in Shanghai's ZhangJiang Science City.
– Former U.S. FDA Officer Dr. Fuxing Tang joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development.

Financial Highlights

– Cash position was approximately RMB1,105.6 million as of December 31, 2019.
– Loss before tax decreased by approximately RMB3,178.7 million or approximately 88.2% to approximately RMB425.3 million.

Future Pipeline Outlook

– The Company plans to announce top-line 52-week Phase III trial result for the monotherapy trial (HMM0301) by no later than third quarter 2020.
– The Company plans to announce top-line 24-week Phase III result for the combination with metformin trial (HMM0302) by no later than third quarter 2020, and top-line 52-week result by year end 2020.
– The Company plans to partner with either China-based or international pharmaceutical companies to make dorzagliatin and related products, as brand new therapies, available to patients, in both China and regions outside of China.
– HMM0109 is a Phase I trial studying the pharmacokinetics profile for hepatic impaired patients in China.
– HMM0112 is a dorzagliatin combination with empagliflozin (a SGLT-2 inhibitor) Phase I trial in T2D patients in the United States. The Company announced the first patient was dosed in April 2019 and expect to complete and announce results by first half 2020.
– In order to continue expansion of dorzagliatin's indications for the treatment of T2D, the Company is investigating the combination of dorzagliatin with various approved classes of oral anti-diabetic medicines and expand the dorzagliatin-driven portfolio to address patients' personal needs.

About Dorzagliatin
Dorzagliatin is a first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in people with type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of people with type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.

About Hua Medicine
Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of type 2 diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.



Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

ASGE Releases Recommendations for Endoscopy Units in the Era of COVID-19

DOWNERS GROVE, IL / ACCESSWIRE, Mar 14, 2020 – (ACN Newswire) – The American Society for Gastrointestinal Endoscopy (ASGE) has released an important article in its signature publication, the Gastrointestinal Endoscopy (GIE) journal. The article, titled "Coronavirus (COVID-19) Outbreak: What the Department of Endoscopy Should Know", is written by ASGE member, Dr Alessandro Repici and his colleagues who have first-hand experience and are still in the middle of the COVID-19 crisis in Italy.





Endoscopy is a place where patients and physicians have very close distance and physicians are exposed to splashes, mucus or saliva during procedures especially upper gastrointestinal (GI) endoscopy. Moreover oral-fecal transmission has been postulated as a potential route for COVID-19 transmission. Endoscopy is also a place with significant concentration of people (staff, patients, caregivers, relatives, etc.) This is why establishing detailed and strict rules is of paramount importance to protect both personnel and patients.

Even though health care personnel working in endoscopy units are not directly involved in the diagnostic and therapeutic evaluation of COVID-19 positive patients, endoscopy should still be regarded as a risky procedure. This risk of exposure and subsequent infection of endoscopy personnel is, in fact, substantial in cases of patients with respiratory disease that can be spread via an airborne route.

The risk of exposure of endoscopy personnel is also not limited to upper endoscopy procedures, considering the recent detection of SARS-CoV in biopsy specimens and stools, suggesting a possible fecal-oral transmission. This could be even more relevant given that the virus transmission can occur during the incubation period in asymptomatic patients.

Establishing infection prevention measures and guidelines within an endoscopy department is essential for creating a high-quality and extremely safe environment to protect both patients and personnel. In this new era of the COVID-19 outbreak, it is imperative that these measures be implemented and maintained to avoid further spread of the disease.

"We recognize that ASGE members and their patients globally need to be diligent in maintaining individual health while minimizing disruption to day-to-day endoscopic practices and overall regional economies," said John Vargo, MD, FASGE, President of ASGE. "It is a challenging time for the whole world, and endoscopists and physicians have the additional responsibility of protecting both patients and their own well-being."

Read the GIE article. https://pr.report/IWK3r6dG

ASGE would like to express its appreciation to the authors for sharing their first-hand experience with other medical professionals around the world. They are currently in the middle of providing critical patient care at their medical institution, but felt it was important to also share their knowledge to minimize the global impact of this outbreak.

About the American Society for Gastrointestinal Endoscopy

Since its founding in 1941, the American Society for Gastrointestinal Endoscopy (ASGE) has been dedicated to advancing patient care and digestive health by promoting excellence and innovation in gastrointestinal endoscopy. ASGE, with more than 15,000 members worldwide, promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit www.asge.org and www.screen4coloncancer.org for more information and to find a qualified doctor in your area.

For more information, contact:
Andrea Lee
Director of Marketing and Communications
American Society for Gastrointestinal Endoscopy
3300 Woodcreek Dr.
Downers Grove, IL 60515
USA
alee@asge.org
+1-630-5705603

SOURCE: American Society for Gastrointestinal Endoscopy

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Agilex Biolabs Announces 30% Labs Expansion and Offers Virtual Lab Tours During COVID-19 Outbreak

Adelaide, AUS, Mar 13, 2020 – (ACN Newswire) – Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has expanded its lab facilities by more than 30% to accommodate demand, mainly from US and APAC-based biotech companies.





As the only FDA-inspected lab of its type in the region, Agilex is located in Adelaide, South Australia, in a science and biotech specialist hub.

The company specialises in bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS and Immunoassay (MesoScale, Gyrolab).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
– Immunophenotyping
– Receptor occupancy
– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine / biomarker profiling
– PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs CEO Jason Valentine said they will now be offering virtual tours of the lab for customers who have travel restrictions during the current Covid-19 outbreak.

CEO Jason Valentine said:

"Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma / biotechs from US, Europe and APAC.

"By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.

"Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition."

Learn more:
– Watch the Agilex Biolabs video: https://youtu.be/3lyodiqqM_k
– Download the New Services data sheet: https://tinyurl.com/AgilexBiolabs

About Agilex Biolabs
Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980's, and has now grown into a global business for early phase clinical trials. In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world. Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA. Call +61 8 8302 8777 or +1 800 247 1909 or visit https://www.agilexbiolabs.com/.

Media Contact:
Team@DMGPR.Com
David James
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

1929 Mask launches Antimicrobial Masks to counter Coronavirus

SINGAPORE, Mar 12, 2020 – (ACN Newswire) – Keenon Lee, founder of Singapore-based 1929 Mask, has announced the launch of 1929 Antimicrobial Face Masks, easing pressure on the global supply of masks created by the spread of Coronavirus. With an increasing number of individuals affected by the virus, the product launch has arrived at the right time.





1929 Mask produces masks that are water repellent, antimicrobial and reusable with technology that eliminates bacteria and fungus, and allow for odour control, freshness and hygiene. The masks are non-toxic and eco-friendly with a high degree of efficacy and durability, resistant for more than 100 washes with textiles.

The 1929 Mask comprises three layers: the outermost layer is water repellent, the center layer is antimicrobial, and the innermost layer is moisture wicking to maintain user comfortable. Each layer in the mask has undergone rigorous, individual testing. and our masks are certified safe and effective, using active ingredients approved by the FDA, EPA and WHO.

"The greatest way to prevent catching coronavirus, as well using a 1929 Branded Mask, is to delay any trips to places with known outbreaks," says Lee. "You can also wash with your soap; avoid touching the eyes, nose and mouth with unwashed hands, and avoid close contact with those who are sick."

It is common in some countries to observe individuals donning masks in public to protect against pathogens, however those masks help little with a virus. "Those masks are not designed to keep out viral particles and they're not as fitted around the nose and cheeks," he continued.

Most of the reusable masks are not tested, and are little more than common dust masks used in construction and other industries where airborne particulates are found. Some are using surgical masks, as they are sick with a cold and don't wish to contaminate others. "If you're sick, it's best not to go to public places. That's the time to stay at home," he said.

Lee advised of five things people should remember:
1. Before putting on a mask, clean hands with alcohol-based hand rub or soap and water.
2. Be sure to cover your mouth and nose with a mask.
3. Avoid touching the mask while using it; if you do, clean your hands.
4. Replace the mask with a new one as soon as it is damp, and do not reuse single-use masks. Brand 1929 Microbial masks are reusable.
5. To remove the mask: remove it from behind (do not touch the front of mask); discard in a closed bin; clean hands with alcohol-based hand rub or soap and water.

1929 Mask Pt Ltd is dedicated to creating innovative, efficient and eco-friendly mask solutions to reduce stress on the supply of face masks in the healthcare system. For more information, visit the company's website at https://1929mask.com, or contact Keenon at info@1929mask.com.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Radiologex Partners with Trusona to Bolster User Auth Security for Innovative Healthcare Industry Software

IRVINE, CA, Mar 12, 2020 – (ACN Newswire) – Radiologex announced this week that it has partnered with Trusona, the pioneering leader of passwordless authentication, for its new all-inclusive software for medical doctors, healthcare professionals and healthcare companies. Radiologex(R) or RDEE for short, pronounced [AR-Dee], is the world's first and only one-stop software ecosystem exclusively for the healthcare industry, powered by blockchain technology, and now protected by the highest level of security. The Radiologex product is especially relevant in light of the current novel coronavirus crisis and other health emergencies where the speed, efficiency and confidentiality of communications and data transmission is paramount.





Radiologex is a real-time productivity, collaboration and information resource available via portable device-based app or via the Web. Its advanced user-authentication technology and builtin KYC (Know Your Customer) now includes a state of the art usernameless and passwordless authentication option that was developed by Trusona, the world leader in the field that holds some of the largest financial services and health care companies as clients.

"Compromised credentials are responsible for over 80 percent of breaches. Trusona's mission is to thwart cybercrime by eliminating static credentials from the user experience," said Ori Eisen, Founder and CEO at Trusona. "Radiologex has set the bar high for security within its product and we have integrated our stringent cutting-edge safeguards into their software engine."

"The recent appearance of novel coronavirus, and the very real possibility of a pandemic, is illuminating the need for a one stop instant communications platform dedicated for the healthcare industry, that is also equipped with a full suite of relevant services and productivity enhancing tools, allowing healthcare professionals to carry out various tasks in the most efficient manner when timing is critical. Yet in providing such services, Radiologex does not want to sacrifice security. Secure and safe transmission of information will always remain a top priority for Radiologex," said John Kiyo Smith, CEO, Radiologex.

"Trusona is the only company anywhere in the world that can provide technological solutions that meet our strict standards for security. We are confident our partnership with Trusona will serve to foster trust and peace of mind among Radiologex customers, and is a natural fit with our game changing platform."

Radiologex is the industry's first and only Web 3.0 solution, encompassing productivity tools; clinical information systems; medical imaging processing and storage; entire payment settlement and lending/finance systems; medical supplies, devices and equipment sales and repair services; content on demand; and a dedicated online community. The Radiologex team is comprised of experienced professionals with diverse backgrounds including medical physicians, healthcare service providers (e.g. radiology), and information systems and software developers with blockchain and distributed ledger technology expertise.

"The healthcare industry is highly vulnerable to security breaches and transactional bottlenecks, negatively affecting patient care, including critical care logistics, from start to finish. Radiologex solves for all of that in one easy-to-use platform with safety and speed built in as the vanguard, and partnering with Trusona only serves to enhance these capabilities," says Radiologex Co-founder, George Tyler.

"I headed a study with our team to uncover the primary pain-points experienced by the healthcare industry associated with the SARS epidemic of 2002, which is a scaled-down version of what we are currently experiencing with this COVID-19 event. The primary pain-point we discovered was the unavailability of a streamlined and dedicated communications platform among healthcare providers, which substantially hindered their ability to determine optimal courses of action in a time efficient manner. There was a dearth of communication amongst healthcare providers, large and small, including all levels of government, that was highly uncoordinated, leading to misinformation and contradictory information being disseminated to the public.

"RDEE's messenger module solves for this by offering the only available real-time, dual end encrypted, user KYC'd solution for the entire healthcare industry and even governments, with Trusona technology serving as the gateway for seamless yet ultra-secure access from anywhere. Healthcare professionals will no longer be required to physically be at their respective organizations or login via a cumbersome VPN process on their laptops to establish a wide-ranging communications channel with their colleagues. With Radiologex and Trusona technology, they can now establish unlimited communications channels instantly, from any portable device or web portal, from anywhere in the world, all without remembering a username or password. It will literally be that easy.

"The second major pain-point we discovered was the unfortunate price-gouging of prized medical goods, services, and products essential to containment, which would be subdued by RDEE's Marketplace and Service-on-Demand modules, providing real time global verified product and vendor authenticity, as well as instant, borderless, transactional capacity that can get these goods and services where they need to be with never-before-seen efficiency and swiftness, thanks in no small-part to secure ease of access facilitated by Trusona," added George Tyler.

Trusona (www.trusona.com), founded in 2015 by cybersecurity expert Ori Eisen, is the pioneer and world leader in passwordless authentication. Over 200 organizations, including some of the world's largest financial services and health care companies, rely on Trusona's solutions.

Radiologex (www.radiologex.com) technology is utility patent-pending, tested and certified by the Office of the National Coordinator for Health Information Technology of the U.S. Department of Human and Health Services. The platform is available worldwide with free to use capacities for all users in April 2020.

For more information, contact Drew Saunders at Launch@radiologex.com, Tel (800) 640-2198 or https://radiologex.com. Follow us on Twitter.com@Radiologex and Telegram.com/RadiologexOfficialGroup.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Further Analyzing Coronavirus Cases against Average Temperatures

TOKYO, Mar 11, 2020 – (ACN Newswire) – A group of consultants at Azabu Insights Inc., a strategic consulting company in Azabu Juban Tokyo, have been analyzing data to understand the correlation between air temperature and spread of the coronavirus (Covid-19).



1. Outbreak in Japanese Prefectures, Mapped Against Average Temperature Celsius


2. Total Infection Cases, Countries with more than ten Covid-19 cases (excl. China)


3. Total Infection Cases, Countries with more than ten Covid-19 cases (incl. China)


4. Percentage of Top 51 Countries with Outbreaks


5. Percentage Case Increases by Selected Region


6. Case Counts and Monthly Temperatures, 51 Countries with more than ten Covid-19 cases



Last week we made the case that coronavirus seems to be spreading more in colder countries than in warmer countries and that there might be some respite for the Northern Hemisphere countries if we can make it to the warmer part of spring without numbers jumping up too aggressively.

This weekend we analyzed more data, more carefully, in two geographic models. First, we analyzed the number of cases in each of Japan's forty-seven prefectures (akin to States in the US). Second, we looked at countries and their mean monthly temperatures. Lastly, we looked at velocity of growth.

Japan Cases Overrepresented in Colder Prefectures

Japan is interesting to look at. Despite having only 126 million people living in 377,900 square kilometers (about the size of Montana), it spreads North and South from latitudes in line with Maine and Florida. The temperature dispersion is, not surprisingly, significant. Okinawa, which has about the same latitude as Miami, Florida, had an average February temperature of 16 degrees celsius (61 fahrenheit), whereas Sapporo, which has a latitude similar to Portland, Maine, had an average temperature of minus 4.2 degree celsius (24.4 fahrenheit).

In the below chart we included all of the prefectures of Japan, sorting them with the most Coronavirus infections at the top and going all the way down to zero infections at the bottom. An analysis of the prefectures below shows a number of interesting insights. First off we see that all of the areas with significant infection counts are considered either cold or very cold in February. Okinawa, as mentioned, is a warmer prefecture and had only three cases despite being one of the areas with many Chinese tourists.

We color coded the average temperatures across prefectures for every month of the year (the average of low and high temperature) into five categories, as below. The next insight is that most of the prefectures will need to wait until April or May to reach the February temperatures of Okinawa; temperatures will remain high through October.

1. Outbreak in Japanese Prefectures, Mapped Against Average Temperature Celsius
http://www.acnnewswire.com/topimg/Low_Azabu20200310-1.jpg

International Outbreak vs Temperature: 94-98% of Cases in Cold Regions

We next analyzed the international outbreak vs. temperature. Again, some interesting insights come through. First off we noticed that fourteen of the top fifteen countries were all "very cold" or "cold" in February. One country, Spain, was classified as "middle" temperature; it has the seventh most cases (as of March 8, 2020). Spain had an average temperature of eight degrees in February which, while certainly not hot, was somewhat warmer than the average of three degrees across the top fifteen countries.

Further, we noted that there are currently fifty-one countries with at least ten cases. Of the total number of cases 22,967 or roughly 93 percent were in "cold" or "very cold" regions, excluding China. This number would be 103,655 or roughly 98 percent of cases including China. There were 880 cases in warm and middle regions and 753 in hot regions.

2. Total Infection Cases, Countries with greater than ten Covid-19 cases (excl. China)
http://www.acnnewswire.com/topimg/Low_Azabu20200310-2.jpg

3. Total Infection Cases, Countries with greater than ten Covid-19 cases (incl. China)
http://www.acnnewswire.com/topimg/Low_Azabu20200310-3.jpg

Looking at it on a country basis, just over half of the top fifty-one countries were in cold or very cold regions. Again, we caution not to read too much into this, since the aggregate numbers are skewed so high to cold regions. Cases do exist in many warm countries, but there are less of them and they seem to be spreading less quickly.

Further drilling down we see that Singapore and Hong Kong had 138 and 108 cases respectively, a large number amongst hot countries. These countries have a huge number of Chinese visitors but had surprisingly low outbreak rates. They are also interesting because they are very much "indoor" cities, where many people spend their time in large air conditioned buildings and indoor pedestrian walkways and shopping malls. From our discussions with people in Hong Kong and Singapore and from media reports we know that both cities have worked very aggressively to combat the outbreak. It is unclear whether their success is due to their hard work in combating it or due the temperature support or a combination.

4. Percentage of Top 51 Countries with Outbreaks
http://www.acnnewswire.com/topimg/Low_Azabu20200310-4.jpg

Upcoming Winter in the Southern Hemisphere

One concern that we identified was, as the northern hemisphere warms in May and June, that the Southern Hemisphere would be entering their colder winter months and, as such, potentially see an increase in outbreaks and the speed of spread of coronavirus.

On closer examination however we see that Southern Hemisphere winters are milder than many places in the Northern Hemisphere. For example, Hobart is Australia's coldest city and has an average temperature of 8.2 degrees celsius in July which would be classified as "middle" temperature. Similarly Bloemfontein in South Africa (7.2 degrees) and Santiago in Chile (8.2 degrees) are mild. Note, some smaller cities in the Southern and mountainous areas of South America, have colder temperatures, such as Punta Arenas in Chile with a July temperature of 1.5 degrees.

Overall we are hopeful that the milder Southern Hemisphere winters will result in slower spread and less outbreaks through the middle of 2020.

Long Summers in Many Countries

We see that many countries are clustered closer to the equator. This includes South East Asia, much of South Asia, the Middle East, the majority of Africa and much of South and Central america. Of the 51 countries where we have seen at least 10 cases, 23 of them have 6 months or more classified as "hot", with 13 of these countries "hot" all year round. Following the assertion that coronavirus spread is slower in hotter environments, this high number of hot months bodes well for a slowing of the spread of the virus over the ensuing months.

Conversely, we hold concerns for countries with very short summer seasons, particularly in Northern Europe. Global financial center London in the UK for example, only has 2 hot months for the year as does Amsterdam in the Netherlands. While Russia may see less inflow and outflow of people than London it is an outlier with every month of the year either cold or very cold. The potential for outbreaks and continued spread in these countries remains and should be continue to be monitored closely.

Velocity of Spread

A final insight from the data comes from an analysis of the velocity of growth in warm versus cold regions. We found, when analyzing the ten regions we had previously looked at, that the rate of growth of the cases between March 3 and March 8th was faster in the colder regions (average growth of 185%) than in the warmer regions (average growth of 50%). This is to say, while Singapore had a fair number of cases early, their growth from March 3rd to 8th has been slow (only 25%). Cases for countries, such as Washington State (467%) France (397%), Iran (288%), and Italy (189%) all grew very quickly, during the same period. Amongst warm regions we had reviewed, one concern was Malaysia, which had cases jump 158%.

5. Increase in cases by region
http://www.acnnewswire.com/topimg/Low_Azabu20200310-5.jpg

Within Japan we also looked at velocity and found a major jump in Japan's second largest city, Osaka. Osaka is another cold populous city (8.8 million people) with lots of train travel and public gatherings. Numbers jumped to fifty-five cases from eight cases, a growth of 412%. Local media is reporting that this is connected to a cluster around live music events. Japan has also faced a shortage of masks in the past week, with many convenience stores receiving shipments of only two or three masks at a time. Rough counts on the street seem to show less people wearing masks than a week ago, when they were more available.

Osaka is Japan's second largest city and is home to a number of very famous listed companies, which may be further affected by the outbreak. These include: Takashimaya (TSE1: 8233), Capcom (TSE1: 9697), Teijin (TSE1: 3401), Panasonic (TSE1: 6752), Daikin Industries (TSE1: 6367).

Refer to the table below to view the cases and average temperatures in the fifty-one countries with ten or more cases. Looking at the pattern of temperature rise across the most affected countries, we see that most will need to wait at least until April or May (and some as late as June) to be classified as "warm" or "hot". There is then a respite until about October when temperatures will drop and be very supportive of the virus spread again.

6. Case Counts and Monthly Temperatures for 51 Countries with greater than ten Covid-19 cases
http://www.acnnewswire.com/topimg/Low_Azabu20200310-6.jpg

Conclusions

As with our previous article, we conclude that Covid-19 can spread in warm regions but seems to spread much more quickly in colder regions. We hope that countries and regions around the world will aggressively work to keep the virus at bay until the summer months and hope that the warm temperatures will support further containment.

Comments on our analysis are welcome at the email below.

About Azabu Insights

Azabu Insights is a boutique strategic consulting company based in Azabu Juban, Tokyo, Japan. Our teams work collaboratively with clients to build strategies that lead to positive change. Our multilingual team members have top tier academic backgrounds and deep industry experience that we leverage to provide first class, fully engaged, strategic consulting. Core specializations include life sciences, finance, electronics, automotive, aerospace and other industries. For more information contact: info@azabuinsights.com.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Leading the Industry in Germany for Years, EuroEyes To Provide China with Vision-Correcting Power

HONG KONG, Mar 10, 2020 – (ACN Newswire) – This famous Chinese saying is believed to be the true portrayal of every successful company during its development phase. Standing on the top of the world, those are the companies that have undoubtedly succeeded more than their competitors to reach the peak.



EuroEyes was awarded "The World Champion in implanting the most Zeiss trifocal lenses worldwide"



EuroEyes opened its first ophthalmology clinic in Hamburg, Germany in 1993. From the company's beginning, EuroEyes has combined technological innovation with exceptional service as it established itself as a leader in the field of ophthalmology and vision correction. As early as in 1986, Dr. Jorn Slot Jorgensen, the founder and chairman of EuroEyes, provided outpatient cataract surgery in Hamburg. Over three decades later, Dr. Jorgensen continues to use world-recognised and advanced diagnostic technology and equipment when treating patients. For the past 26 years, under the direction of Dr.Jorgensen, EuroEyes, has led the industry in advancing vision correction treatments. The company was one of the first to use innovative technologies such as LASIK surgery and phakic lens (ICL) surgeries in the field. In 2004, EuroEyes began using the more advanced blade-free LASIK and in 2014, the company added ReLEx SMILE to its services. EuroEyes has also led the industry by being one of the first-movers to offer Zeiss trifocal lens exchange surgery as a standalone treatment option to presbyopia in its 26 ophthalmology clinics located in Germany, Denmark and China.

No. 1 in the world
Within the international ophthalmology industry, EuroEyes' achievements have long exceeded its peers. This is not merely reflected in its consistent top ranking in the industry for advanced lens exchange surgery and refractive surgery (excluding PRK / LASEK) in Germany and Denmark but also in the number of the cutting-edge vision correction operations performed. In 2018, EuroEyes was acknowledged by Staar Surgical for having performed the most phakic lens (ICL) surgeries in Europe. EuroEyes was also recognized by Carl Zeiss for having performed the most ReLEx SMILE procedures in Germany and the most trifocal lens exchange surgeries in the world for five consecutive years. Carl Zeiss is the leading German manufacturer of optical systems and optoelectronics with 37.6% of its revenue generated from the Trifocal lens. The ZEISS award reflects EuroEyes' leading position in the global application of Trifocal IOL Implantation.

According to market analysis, the use of trifocal IOL implantation is an ideal treatment for presbyopia. Presbyopia usually occurs after the age of 45 when the eye lens loses its elasticity, making it difficult to focus on nearby objects. After the trifocal IOL implantation, patients with myopia and presbyopia can easily and clearly focus on near, medium and distant things without glasses. Furthermore, lens replacement surgery is an ideal treatment for cataracts eliminating the need to wear thick glasses or special contact lenses.

Huge opportunity for market growth as 560 million Chinese people predicted to have presbyopia by 2024
As people better understand the benefits of lens replacement surgery, the number of people undergoing the procedure around the world continues to rise. According to Frost and Sullivan, from 2014 to 2018, the market size of advanced lens exchange surgery and refractive surgery (excluding PRK / LASEK) in Germany and China increased at a compound annual growth rate (CAGR) of 9.3% and 37.8%, respectively. An aging population combined with an increasing desire for improved vision and quality of life, as well as increasing consumption power is motivating more and more people to undergo trifocal IOL replacement surgery. Industry analysts predict that from 2018 to 2023, the market size in Germany and China will expand at a CAGR of 7.2% and 29.5%, respectively.

According to the U.S. Census Bureau's 2019 refractive surgery market report, 50% of Germany's population have presbyopia while 36.4% of China's population have the condition. With over 1.4 billion people living in China, approximately 505 million Chinese people have presbyopia. Industry analysts expect that by 2024, 39.6% of the population in China or about 557 million Chinese people will have presbyopia. Currently the penetration rate of the most advanced Trifocal IOL exchange surgery is very low in China. In 2018, the penetration rate in Germany was 4.3 times that of the Chinese market. In other words, China's Trifocal IOL replacement surgery market has tremendous upside potential for growth.

Euroeyes has received the Zeiss Award for five consecutive years in recognition of the company's excellent lens exchange technology and equipment, strong brand, and exceptional German medical standards and quality. The company is well positioned to provide Chinese customers with international leading lens exchange surgery as it becomes the go-to vision- correcting source in China. EuroEyes is in the early stage of rapidly expanding in the Chinese market. The company's successful listing on the Main Board of the Hong Kong Stock Exchange Limited at the end of last year has provided them with the capital to open additional clinics. Within two months after listing, EuroEyes confirmed the expansion plan of two new eye clinics located in Chongqing and Fuzhou. The two new clinics combined the previous six clinics in Shanghai, Beijing East, Beijing West, Guangzhou, Shenzhen, Hangzhou, brings the total number of Euroeyes' clinics to eight in total. The company intends to open two additional clinics in Chongqing and one in another top tier city in the future.

According to the company's financial report, revenue generated from China in 2018 was about 94 million Yuan, accounting for 28.2% of the company's global revenue. The CAGR for revenue and gross profit in the past three years were 85.1% and 633.7%, respectively. We are looking forward to announcing the full year performance for 2019!



Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

SOE Hospitals Holding Pertamedika set to tackle Coronavirus Spread

JAKARTA, Mar 9, 2020 – (ACN Newswire) – Indonesia's government, through the State-Owned Enterprise (SOE) Ministry, instructed government-owned hospitals in the Indonesian Healthcare Corporation (IHC) Pertamedika to establish crisis centers and isolation rooms during the emergency period to handle the spread of coronavirus (COVID-19).



Ministry of SOE of Republic of Indonesia Erick Thohir



Moreover, the hospitals should be equipped with other medical supplies, including long-sleeves biohazard gowns, aprons, disposable head caps, N95 masks, safety goggles, gloves, and boots.

"State-owned hospitals are located in almost every area in Indonesia. Hence, crisis centers should be built as a precautionary measure against the emergence of patients suspected of having contracted the coronavirus," Minister of State-Owned Enterprises Erick Thohir noted in a statement received here, Monday.

Reports were received of at least six confirmed cases of COVID-19 since March 2. All six patients are being quarantined in Jakarta.

In response to the first few confirmed cases in Indonesia, IHC Pertamedika, a network of 65 state-owned hospitals across Indonesia, prepared supporting facilities and COVID-19 alert teams, as well as standard operational procedures to handle coronavirus cases.

Chief Executive Officer of IHC Pertamedia, Dr Fathema Djan Rachmat stated that negative pressure isolation rooms were prepared to handle the increasing number of patients.

"We are also considering the construction of a field hospital equipped with various treatment facilities for coronavirus patients," she stated.

Rachmat spoke of innovations made to the tracking system for suspected COVID-19 cases. The Chinese government has successfully applied such tracking systems.

"We are ready to conduct this simulation," she emphasized.

Furthermore, other SOEs have contributed to the efforts to prevent the spread of coronavirus in the country, including the SOE in the pharmaceutical field, Bio Farma, which has begun the research for a COVID-19 vaccine.

PT Angkasa Pura I and II, operational management companies of the country's airports, had prepared isolated parking areas for aircraft that came in from countries with confirmed coronavirus infections.

Meanwhile, SOEs in the transportation sector, including railway management company PT Kereta Api Indonesia, have activated their onboard clinics and inspections on several routes. — Antara.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com